Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study
NCT ID: NCT03578796
Last Updated: 2024-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
31 participants
OBSERVATIONAL
2017-05-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Advances in Telephone-based Cognitive Screening Procedures
NCT06337578
Experimentation of a Personalized Physical Self-education Program at Home: Feasibility Study (PROSOL TELEKINECT)
NCT05597592
Multimodal Assesment of Alzheimer Patients
NCT06448403
Test and Usability of Mixed-reality Screening Tool for Early Detection of Cognitive Declines
NCT05403814
The Effect of Case Conferencing in Nursing Homes
NCT02790372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One of the major challenges in ALS management is the decision-making on advanced therapy. There is a lack of knowledge in how cognitive impairment in ALS shall be interfere on complex medical treatment that will affect quality of life or life itself. This means significant implications not only to the ALS patient and the community, but also the family and especially the spouse. Thus, further investigation of the ECAS-N and its potential in clinical use is needed. The scale may contribute a more proactive treatment better tailored to individual needs. The objective is to evaluate if the ECAS-N can be applied as an early predictor in car-driving, working and use of advanced life-prolonging therapy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Persons with ALS
Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
ECAS-N
assessing ALS-specific cognitive impairment
MoCA
assessing cognitive impairment
CDR
assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
Questionnaire
Questions related to work situation and car driving
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ECAS-N
assessing ALS-specific cognitive impairment
MoCA
assessing cognitive impairment
CDR
assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
Questionnaire
Questions related to work situation and car driving
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Native Norwegian speaker
Exclusion Criteria
* Comorbid medical history
* Neurological disorders others than ALS
* Psychiatric history of importance to cognitive function
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Western Norway University of Applied Sciences
OTHER
Haukeland University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tina Taule, PhD
Role: PRINCIPAL_INVESTIGATOR
Haukeland University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Haukeland University Hospital
Bergen, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016/2187-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.